Skip to content

Quick ratio at other companies

Castle Biosciences logo
Castle BiosciencesCSTL
6.5×-2.7×
Guardant Health logo
Guardant HealthGH
4.4×+0.6×
Biodesix, Inc. logo
Biodesix, Inc.BDSX
2.8×+0.6×
Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
2.5×-1.2×
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
5.3×-1.0×
Personalis, Inc. logo
Personalis, Inc.PSNL
6.6×-0.3×

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Calculated from Lucid Diagnostics’s reported figures.

Based on the most recent quarter.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's quick ratio?
Lucid Diagnostics (LUCD) reported quick ratio of 1.1× in Q1 2026.
How has Lucid Diagnostics's quick ratio changed year-over-year?
Lucid Diagnostics's quick ratio increased by 42.1% year-over-year, from 0.7× to 1.1×.
What is the long-term trend for Lucid Diagnostics's quick ratio?
Over 4 years (2021 to 2025), Lucid Diagnostics's quick ratio has grown at a -44.3% compound annual growth rate (CAGR), from 13.5× to 1.3×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.